The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
Official Title: A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study
Study ID: NCT02780089
Brief Summary: This study evaluates the different patterns of care for patients who have unresectable or metastatic melanoma. The dosing, duration, regimen, indication, and treatments will be observed. The survival rate of these patients will also be observed.
Detailed Description: This is a non-interventional, observational study with the primary objective to assess and describe "real world" patterns of care in the treatment of patients with unresectable or metastatic melanoma. A sample size of 1,600 prospective patients will provide sufficient information to explore this primary objective. There will be no forced number of patients enrolled into a specific treatment cohort. Setting or controlling specific treatment enrollment cohort counts would invalidate the results of the primary objective of the study. No primary hypothesis is being tested.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States
Genesis Cancer Center, Hot Springs, Arkansas, United States
Pacific Shores Medical Group, Long Beach, California, United States
Cancer Care Associates, Redondo Beach, California, United States
University of Colorado, Aurora, Colorado, United States
21st Century Oncology, Jacksonville, Florida, United States
Cancer Specialits, LLC D/B/A, Jacksonville, Florida, United States
Lakeland Regional Health, Lakeland, Florida, United States
Watson Clinical Center for Research, INC, Lakeland, Florida, United States
UF Health Cancer Center at Orlando Health, Longwood, Florida, United States
Mount Sinai Medical Center, Miami Beach, Florida, United States
Mid Florida Hematology and Oncology Centers, Orange City, Florida, United States
Sacred Heart Medical Oncology Group, Pensacola, Florida, United States
Tallahassee Memorial Healthcare, Tallahassee, Florida, United States
H. Lee Moffitt Cancer Center Moffitt Cancer Center, Tampa, Florida, United States
Harbin Clinic, Rome, Georgia, United States
Summit Cancer Care, Savannah, Georgia, United States
The Queen's Medical Center, Honolulu, Hawaii, United States
North Shore University Health System, Evanston, Illinois, United States
Ingalls Cancer Research Center, Harvey, Illinois, United States
Oncology Specialits, S.C., Niles, Illinois, United States
Orchard Healthcare Research Inc., Skokie, Illinois, United States
Simmons Cancer Institute at SIU School of Medicine, Springfield, Illinois, United States
Stormont-Vail Cancer Center, Topeka, Kansas, United States
University of Kansas Medical Center, Westwood, Kansas, United States
West Ky Hematology & Oncology, Paducah, Kentucky, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
CHRISTUS Schumpert Cancer Treatment Center, Shreveport, Louisiana, United States
Saint Agnes Hospital, Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Masonic Cancer Center, Minneapolis, Minnesota, United States
Mayo Clinic Cancer Center (MCCC), Rochester, Minnesota, United States
Forrest General Cancer Center, Hattiesburg, Mississippi, United States
Central Care Cancer Center, Bolivar, Missouri, United States
Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States
Oncology Hematology West P.C., Omaha, Nebraska, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Atlantic Health, Morristown Medical Center, Morristown, New Jersey, United States
Meridian Health, Neptune, New Jersey, United States
Rosewell Park Cancer Institute, Buffalo, New York, United States
Center of Learning Healthcare, Durham, North Carolina, United States
Hematolgoy and Oncology Associates, Inc., Canton, Ohio, United States
Aultman Hospital, Canton, Ohio, United States
Tri-County Hematology and Oncology Associates, Inc, Massillon, Ohio, United States
Genesis Cancer Care Center, Zanesville, Ohio, United States
St. Charles Medical Center - Cancer Center, Bend, Oregon, United States
Network Office of Research & Innovation / Lehigh Valley Health Network, Allentown, Pennsylvania, United States
St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States
The Regional Cancer Center, Erie, Pennsylvania, United States
Lancaster General Health, Lancaster, Pennsylvania, United States
Jefferson Medical Oncology, Philadelphia, Pennsylvania, United States
Allegheny Health Network, Pittsburgh, Pennsylvania, United States
UPCI - UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
Thompson Cancer Survival Center, Knoxville, Tennessee, United States
Texas Oncology, Austin, Texas, United States
Texas Oncology, El Paso, Texas, United States
Texas Oncology, Paris, Texas, United States
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States
Providence Regional Medical Center Everett, Everett, Washington, United States
Cancer Care Northwest, Spokane, Washington, United States
West Virginia University, Bridgeport, West Virginia, United States
West Virginia University, Huntington, West Virginia, United States
West Virginia University Hematolgoy & Oncology, Martinsburg, West Virginia, United States
West Virginia University, Morgantown, West Virginia, United States
Gundersen Lutheran Medical Foundations, Inc., La Crosse, Wisconsin, United States
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR